Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
TECH Analyst Ratings
Strong Buy
11 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TECH Stock 12 Month Forecast
Average Price Target
$66.55
▲(13.45% Upside)
| Highest Price Target$75.00 | Average Price Target$66.55 | Lowest Price Target$53.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
$70
Buy
19.33%
Upside
Reiterated
10/07/25
William Blair
―
Buy
―
Reiterated
09/19/25
William Blair Sticks to Its Buy Rating for Bio-Techne (TECH)We hosted investor meetings with Techne CEO Kim Kelderman and CFO Jim Hippel. Meetings focused on the state of the company’s end-markets, key growth drivers, and capital allocation (including Wilson Wolf), which we cover in more detail below. In terms of the stock, the situation is far from simple given multiple uncertainties affecting each of Techne’s end-markets (NIH for academia, funding for biotech, tariffs/MFN for pharma), though at this point we think management’s message has become clearer—that the low-single- digit growth bogey for the “period of uncertainty” will be challenged by tough comps in the first half of fiscal 2026, with no inflection contemplated until second half fiscal 2026/first half calendar 2026.
RBC Capital
$61→$73
Buy
24.45%
Upside
Upgraded
09/02/25
Scotiabank
$75
Buy
27.86%
Upside
Reiterated
08/08/25
Robert W. Baird
$58→$53
Hold
-9.65%
Downside
Reiterated
08/07/25
Stifel Nicolaus
$60
Hold
2.28%
Upside
Reiterated
08/07/25
Wells Fargo
$59
Buy
0.58%
Upside
Reiterated
08/06/25
TD Cowen
$65
Buy
10.81%
Upside
Initiated
08/06/25
Leerink Partners
―
Buy
―
Reiterated
08/05/25
Stephens
$65
Buy
10.81%
Upside
Initiated
07/21/25
Argus Research
$90→$65
Buy
10.81%
Upside
Reiterated
05/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
$70
Buy
19.33%
Upside
Reiterated
10/07/25
William Blair
―
Buy
―
Reiterated
09/19/25
William Blair Sticks to Its Buy Rating for Bio-Techne (TECH)We hosted investor meetings with Techne CEO Kim Kelderman and CFO Jim Hippel. Meetings focused on the state of the company’s end-markets, key growth drivers, and capital allocation (including Wilson Wolf), which we cover in more detail below. In terms of the stock, the situation is far from simple given multiple uncertainties affecting each of Techne’s end-markets (NIH for academia, funding for biotech, tariffs/MFN for pharma), though at this point we think management’s message has become clearer—that the low-single- digit growth bogey for the “period of uncertainty” will be challenged by tough comps in the first half of fiscal 2026, with no inflection contemplated until second half fiscal 2026/first half calendar 2026.
RBC Capital
$61→$73
Buy
24.45%
Upside
Upgraded
09/02/25
Scotiabank
$75
Buy
27.86%
Upside
Reiterated
08/08/25
Robert W. Baird
$58→$53
Hold
-9.65%
Downside
Reiterated
08/07/25
Stifel Nicolaus
$60
Hold
2.28%
Upside
Reiterated
08/07/25
Wells Fargo
$59
Buy
0.58%
Upside
Reiterated
08/06/25
TD Cowen
$65
Buy
10.81%
Upside
Initiated
08/06/25
Leerink Partners
―
Buy
―
Reiterated
08/05/25
Stephens
$65
Buy
10.81%
Upside
Initiated
07/21/25
Argus Research
$90→$65
Buy
10.81%
Upside
Reiterated
05/30/25
Best Analysts Covering Bio-Techne
1 Month
xxx
Success Rate
5/7 ratings generated profit
Average Return
+1.37%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.37% per trade.
3 Months
xxx
Success Rate
6/7 ratings generated profit
Average Return
+6.90%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +6.90% per trade.
1 Year
Success Rate
6/7 ratings generated profit
Average Return
+16.40%
reiterated a buy rating 2 months ago
Copying Dan Leonard's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +16.40% per trade.
2 Years
xxx
Success Rate
6/7 ratings generated profit
Average Return
+16.37%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +16.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TECH Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
4
3
1
0
0
Buy
10
19
20
20
12
Hold
11
7
9
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
29
30
28
20
Each month's total comprises the sum of three months' worth of ratings.
TECH Financial Forecast
TECH Stock Forecast FAQ
What is TECH’s average 12-month price target, according to analysts?
Based on analyst ratings, Bio-Techne’s 12-month average price target is 66.55.
What is TECH’s upside potential, based on the analysts’ average price target?
Bio-Techne has 13.45% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TECH a Buy, Sell or Hold?
Bio-Techne has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
What is Bio-Techne’s price target?
The average price target for Bio-Techne is 66.55. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $53.00. The average price target represents 13.45% Increase from the current price of $58.66.
The highest analyst price target is $75.00 ,the lowest forecast is $53.00. The average price target represents 13.45% Increase from the current price of $58.66.
What do analysts say about Bio-Techne?
Bio-Techne’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of TECH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.